Mounjaro Patent Protection
8 patents · Eli Lilly and Company
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 9474780 | Drug substance & product patent | Eli Lilly and Company | Jan 5, 2036 | 9.5y left |
| 12453755 | Orange Book listed patent | Eli Lilly and Company | Jun 14, 2039 | 13.0y left |
| 12629404 | Drug product (formulation / method-of-use) patent | Eli Lilly and Company | Jun 14, 2039 | 13.0y left |
| 12453756 | Drug product (formulation / method-of-use) patent | Eli Lilly and Company | Jun 14, 2039 | 13.0y left |
| 11357820 | Drug substance & product patent | Eli Lilly and Company | Jun 14, 2039 | 13.0y left |
| 12343382 | Orange Book listed patent | Eli Lilly and Company | Jul 22, 2039 | 13.1y left |
| 12616740 | Orange Book listed patent | Eli Lilly and Company | Jul 22, 2039 | 13.1y left |
| 12295987 | Orange Book listed patent | Eli Lilly and Company | Dec 30, 2041 | 15.5y left |
Related Drug Patent Expirations
1 patents · earliest expires 2031 · Eli Lilly and Company
0 patents · Eli Lilly and Company
0 patents · Eli Lilly and Company
1 patents · earliest expires 2034 · Bayer Intellectual Property GmbH
9 patents · earliest expires 2033 · Gilead Sciences Inc.
5 patents · earliest expires 2032 · AstraZeneca AB
For Mounjaro, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for Mounjaro’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.